

## IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

KAZUHIKO TAKE ET AL

: EXAMINER: BERNHARDT, E.

SERIAL NO: 09/857,869

09/857,869

FILED: JUNE 12, 2001

: GROUP ART UNIT: 1624

FOR: PIPERAZINE DERIVATIVES

**RECEIVED** 

JAN 1 6 2003

**SUPPLEMENTAL AMENDMENT** 

**TECH CENTER 1600/2900** 

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Supplemental to the amendment filed December 20, 2002, and further responsive to the Office Action dated June 20, 2002, Applicants respectfully request reconsideration of the above-identified application in view of the Declaration of Masahiko Matsuo (Matsuo Declaration) and a complete certified copy of priority application Australia PP7706, filed December 14, 1998, **both submitted herewith** and the following remarks.

Claims 11-18 remain pending in the application.

## <u>REMARKS</u>

The Matsuo Declaration is intended to provide declaratory support for the results attached to the amendment filed December 20, 2002, and discussed at pages 6-7 thereof. Note additionally that the attachment incorrectly referred to the "h-NK<sub>1</sub>" receptor as the "h-NH<sub>1</sub>" receptor. The Matsuo Declaration states it correctly.